SPY400.09-1.63 -0.41%
DIA322.78+0.55 0.17%
IXIC11,662.79-142.21 -1.20%

BRIEF-Opiant Pharma, Hikma Report Exclusive $225 Mln Agreement For OPNT003

reuters.com · 04/29/2022 09:44
BRIEF-Opiant Pharma, Hikma Report Exclusive $225 Mln Agreement For OPNT003

- Opiant Pharmaceuticals Inc OPNT:

  • OPIANT PHARMACEUTICALS AND HIKMA ANNOUNCE EXCLUSIVE $225 MILLION COMMERCIALISATION AND LICENSE AGREEMENT FOR OPNT003, NASAL NALMEFENE, IN EUROPE AND THE UK

  • OPIANT PHARMACEUTICALS UK - AS PART OF DEAL, CO WILL RECEIVE $175 MILLION UPFRONT ALONG WITH $50 MILLION IN MILESTONES UPON LAUNCH

  • OPIANT PHARMA UK - IN DEAL, CO IS RESPONSIBLE FOR DEVELOPMENT & FILLING OF OPNT003 & WILL SUPPLY FINISHED COMMERCIAL PRODUCTS FOR EU & UK MARKETS

  • OPIANT PHARMACEUTICALS UK - IN DEAL, HIKMA RESPONSIBLE FOR REGISTERING OPNT003 WITH EUROPEAN MEDICINES AGENCY

  • OPIANT PHARMACEUTICALS UK - HIKMA WILL HAVE EXCLUSIVE RIGHTS TO COMMERCIALISE THE PRODUCT, OPNT003, IN THE EU AND UK, AS PART OF DEAL

  • OPIANT PHARMACEUTICALS INC - CO ALSO ELIGIBLE FOR SINGLE DIGIT TIERED ROYALTIES ON EU AND UK SALES OF OPNT003, AS PART OF DEAL

Source text for Eikon: ID:nPre8Vwhka

Further company coverage: OPNT


((Reuters.Briefs@thomsonreuters.com;))